James Healy

InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA.

ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies.

Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force.

Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California.

CoTherix, Inc. develops therapeutic products. Its ventavis product is a nebulizer delivered therapy for pulmonary artery hypertension, which restricts blood flow to the lungs. CoTherix markets its products in the US, Europe, and Australia. The company was founded in February, 2000 by Donald J. Santel and Gerard Turino and is located in Brisbane, CA.

Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC.

Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA.

InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA.

Sofinnova Venture Partners VII LP invests in companies located in the US and Europe. It targets companies operating in the fields of telecom/wireless, enterprise networking, semiconductors, photonics, and horizontal software technologies. It provides financing for seed, early stage, and corporate spin-outs transactions with investment size ranges from $100,000 to $500,000.It lead or co-lead the transactions and takes a seat on the board of directors. It also makes co-investment.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA.

NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY.

Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Salveo Specialty Pharmacy, Inc. operates as a holding company that engages in the provision of medications and clinical services to patients with chronic conditions. It specializes in organ transplant, stem cell transplant, HIV, hepatitis, oncology, biologics, rheumatoid arthritis, dermatology, and neurology therapies. The company was founded by Jeffrey Freedman and Charles Brown in 2011 and is headquartered in St. Petersburg, FL.

Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California.

Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA.

Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC

Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA.

Movetis NV operates as a pharmaceutical company, that focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, and paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company was founded in November 2006 and is headquartered in Turnhout, Belgium.

National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC.

PregLem SA manufactures and markets pharmaceutical products specializing in gynecology and women's reproductive health. Its products include ESMYA, PGL2001, and PGL1001. The company was founded in June 2006 and is headquartered in Geneva, Switzerland.

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its products portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland.

Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL.

CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA.

Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC.

Sofinnova Investments, Inc. (Investment Management) (Sofinnova-IM) is the investment management division of Sofinnova Investments, Inc., a venture capital firm headquartered in Menlo Park, California. Founded in 1974, Sofinnova-IM serves as an investment adviser to pooled investment vehicles and separately managed accounts.

Rapport Therapeutics, Inc. is an American clinical-stage biotechnology company that focuses on discovering and developing medicines for neurological disorders. The CEO of the company is Abraham N. Ceesay.

Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland.

Durata Therapeutics, Inc. develops and commercializes novel therapeutics for infectious diseases and acute illnesses. The company was founded on November 4, 2009 and is headquartered in Chicago, IL.